Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
AUTOR(ES)
Disis, Mary L.
FONTE
American Society of Clinical Oncology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2754913Documentos Relacionados
- Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
- Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer
- Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer
- C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
- Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors